ARDELYX, INC.
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
ARDX$2.93+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Throughout this 2025 Form 10-K, we have used terms which are defined below:
| 340B Program | Public Health Service’s 340B Drug Pricing Program | HCR | HealthCare Royalty Partners IV, L.P. |
|---|---|---|---|
| AAKP | American Association of Kidney Patients | HCR Agreement | Royalty and Sales Milestone Interest Acquisition Agreement |
| ACA | Affordable Care Act | HHS | Department of Health and Human Services |
| AI Technologies | Artificial intelligence, machine learning and certain automated decision-making technologies | HIPAA | Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder |
| AMP | average manufacturer price | HRSA | Health Resources and Services Administration |
| ANDA | abbreviated New Drug Application | IBS-C | irritable bowel syndrome with constipation |
| API | active pharmaceutical ingredient | IND | Investigational New Drug |
| AstraZeneca | AstraZeneca AB | IRA | Inflation Reduction Act of 2022 |
| ASU | Accounting Standards Update | IRB | Institutional Review Board |
| CCPA | California Consumer Privacy Act, as amended by the California Privacy Rights Act | IT | information technology |
| cGMP | current Good Manufacturing Practice | Jefferies | Jefferies LLC |
| CIC | chronic idiopathic constipation | Kyowa Kirin | Kyowa Kirin Co., Ltd. |
| CKD | chronic kidney disease | Knight | Knight Therapeutics, Inc. |
| CME | Chicago Mercantile Exchange | MDRP | Medicaid Drug Rebate Program |
| CMO | contract manufacturing organization | METiS | METiS Therapeutics, Inc. |
| CMS | Centers for Medicare & Medicaid Services | MHLW | Ministry of Health, Labour and Welfare |
| CRO | contract research organization | MIPPA | Medicare Improvements for Patients andProviders Act |
| Customers | collectively, major wholesalers, specialty pharmacies and GPOs (IBSRELA) and specialty wholesaler (XPHOZAH) | OLC | Oxylanthanum Carbonate |
| DPF | EU-US Data Privacy Framework | NCE | new chemical entity |
| EEA | European Economic Area | NDA | New Drug Application |
| ESPP | Employee Stock Purchase Plan | NHE3 | sodium hydrogen exchange 3 |
| ESRD | End-Stage Renal Disease | NMPA | National Medical Products Administration |
| ESRD PPS | End-Stage Renal Disease Prospective Payment System | NOL | net operating loss |
| EU Patent Package | European Patent Package | NMQF | National Minority Quality Forum |
| Exchange Act | the Securities Exchange Act of 1934, as amended | Non-FAMP | Non-Federal Average Manufacturer Price |
| FASB | Financial Accounting Standards Board | R&D | research and development |
| FDA | Food and Drug Administration | REMS | Risk Evaluation and Mitigation Strategy |
| FFDCA | Federal Food, Drug, and Cosmetic Act | RSU | restricted stock units |
| Fosun Pharma | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | SLR | SLR Investment Corp. |
| FSS | Federal Supply Schedule | SEC | Securities and Exchange Commission |
| FTC | Federal Trade Commission | SOFR | Secured Overnight Financing Rate |
| GCP | Good Clinical Practice | TDAPA | Transitional Drug Add-on Payment Adjustment |
| GDPR | European Union General Data Protection Regulation | UPC | European Unified Patent Court |
| GLP | Good Laboratory Practice | U.S. | United States |
| GPO | group purchasing organization | USPTO | U.S. Patent and Trademark Office |
| GTN | gross-to-net | VA | Department of Veterans Affairs |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.